
Influenza and COVID Vaccinations' Effect on Menstrual Cycles
An influenza vaccine, either given alone or with a COVID-19 vaccine during the follicular phase, was linked to minor changes in the length of the menstrual cycle of less than 1 day, but the length of the cycle bounced back to normal soon after.
METHODOLOGY:
This global retrospective cohort study assessed temporary changes in the length of the menstrual cycle after influenza vaccination (either alone or with a COVID-19 vaccine), addressing gaps in understanding effects of a non–COVID-19 vaccine.
Researchers analysed data of 1501 individuals (age, 18-45 years; non-hormonal contraception users) from a birth control app, of whom 791 received an influenza vaccine alone and 710 received influenza and COVID-19 vaccines concurrently.
The cohort was predominantly younger than 35 years (82.0%), had at least a college degree (74.8%), and was located in the United States or Canada (62.5%). Racial/ethnic data were missing for 72.2% of participants; 24.5% of participants were identified as White. The average length of pre-vaccination cycles was 24-38 days.
Researchers analysed prospectively tracked cycles (April 2023 to February 2024) and compared each participant's pre-vaccination cycles at baseline (three cycles) with the vaccination cycle. The adjusted change in the mean length of the cycle was the primary outcome.
This study compared average changes in the length of the cycle during vaccination between influenza alone and influenza + COVID-19 vaccine groups and looked at post-vaccine and large changes in the length of the cycle (≥ 8 days).
TAKEAWAY:
Influenza vaccination alone led to a 0.40-day increase in the length of the menstrual cycle, whereas concurrent influenza + COVID-19 vaccination led to a 0.49-day increase, with no significant difference observed between two groups ( P = .69).
= .69). A change in the length of the cycle of 8 days or more occurred in 4.7% of influenza-only recipients vs 5.9% of dual-vaccine recipients; however, the difference was not statistically significant ( P = .28).
= .28). Vaccination during the follicular phase led to a significant increase in the length of the cycle (0.82 days for influenza alone and 0.99 days for dual vaccines).
Post-vaccination lengths of the cycles normalised, with mean changes of −0.02 days for influenza alone and 0.14 days for dual vaccines compared with baseline ( P = .46 for the between-group difference).
= .46 for the between-group difference). Individuals vaccinated in the luteal phase showed no significant changes in the length of the cycle (−0.16 days for influenza alone vs −0.14 days for dual vaccines).
IN PRACTICE:
"In this cohort study of individuals with regular menstrual cycles, influenza vaccine given alone or in combination with a COVID-19 vaccine was associated with a small but temporary change in menstrual cycle length. These findings may help clinicians confirm the utility of vaccination for patients with concerns about menstrual adverse effects of vaccination," the authors of the study wrote.
SOURCE:
This study was led by Emily R. Boniface, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon. It was published online on April 29, 2025, in JAMA Network Open.
LIMITATIONS:
The study's high levels of missing demographic data and a mostly young, White, highly educated sample could have limited how widely these results apply. Self-reported vaccine dates could have recall errors. Incomplete cycle data led to exclusions, and unmeasured factors might still influence the findings.
DISCLOSURES:
This study was supported by a grant from the US National Institute of Child Health and Human Development. Several authors reported receiving grants, honoraria, personal fees, and travel fees from various sources.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
25 minutes ago
- Forbes
The U.S. Government Is Stuck With SpaceX. But Trump Can Still Hurt It.
Donald Trump and Elon Musk arrive for a test launch of SpaceX's Starship rocket on November 19, 2024, in Brownsville, Texas. In the barrage of attacks that President Donald Trump and Elon Musk fired at each other Thursday, one stood out: Trump's threat to cancel federal contracts with companies owned by the world's richest man. The primary target: SpaceX, which has received at least $21 billion in government contracts, with about $13 billion still outstanding. Musk probably doesn't have much to fear. Legally, the Trump administration would likely enmire itself in lengthy legal disputes if it appeared to cancel contracts out of spite. Moreover, as the world's No. 1 launch provider and maker of low-Earth orbit satellites, SpaceX may have made itself indispensable. 'The [U.S. government] is simply too locked in to cut them off over a social media meltdown,' said Kimberly Siversen Burke, director of government affairs at the consultancy Quilty Space. Nonetheless, there are some types of contracts that could be vulnerable for cancellation, and ways the government could lessen its dependence on SpaceX going forward. The 134 rockets SpaceX launched last year accounted for 83% of all satellites put into orbit worldwide. With its reliable, partially reusable Falcon 9, the company has come to dominate U.S. national security launches. Its chief competitor, United Launch Alliance, a joint venture of Boeing and Lockheed Martin, has struggled to keep up, with multiyear delays in developing its new Vulcan rocket. The U.S. government may have more options to carry its military satellites to space going forward. Vulcan is now operational and Blue Origin, the space company founded by Musk's billionaire rival Jeff Bezos, pulled off a successful first launch of its New Glenn rocket in January. In the latest round of contracts awarded by Space Force, SpaceX won 28 launches from 2027 through 2032, a little more than half, with ULA getting 19 and Blue Origin seven. But ULA and Blue Origin have their hands full scaling up, said Todd Harrison, a defense and space analyst with the American Enterprise Institute. 'There's no replacing SpaceX. You just do not have the capacity in our other launch options.' SpaceX has also become a major supplier of national security satellites. The National Reconnaissance Office is depending on SpaceX to build out a multibillion-dollar network of hundreds of spy satellites in low-Earth orbit based on the company's Starshield platform. For delivering cargo and astronauts to the International Space Station, NASA has also had to rely on SpaceX, as Boeing has struggled to fix defects in its Starliner spacecraft. But there are some relatively small-dollar SpaceX contracts that could be vulnerable, said Burke. The government could lower its exposure to SpaceX by looking for early phase development programs that don't have a contractor locked in yet. For example, SpaceX has won roughly $140 million in contracts on an Air Force program to test whether commercial satellite services can be integrated into tactical military communications, Burke said. Another way Trump could hurt Musk, as well as Ukraine, would be to cancel or reduce a $537 million contract to provide Starlink satellite communications services to the Ukrainian military. But rather than targeting existing contracts, where the administration could make a greater impact is by steering new business to others and reorienting its plans. The Commerce Department could backtrack on a revamp announced in March to a $42 billion program to expand rural broadband access that was expected to make Starlink eligible to compete for grants. Till now the program has only included telecom companies laying fiber-optic cables. Trump could also pull back from the support he promised in his inaugural address for Musk's ultimate ambition: to reach Mars. 'Where Trump can single handedly harm SpaceX in a significant way is redirecting the mission goals for NASA,' Harrison said. Given how mercurial Musk has proven to be, perhaps diversifying away from SpaceX isn't a bad idea. Burke worries, however, that the bad blood will undo years of work to convince the Pentagon and other national security agencies that they can rely on any commercial companies. 'Elon's antics are threatening to rewind the tape,' she said. MORE FROM FORBES


Forbes
30 minutes ago
- Forbes
How AI Is Helping Cancer Patients: Saving Lives And Money
Medical technology concept. Medical doctor. getty Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times the cost of treatment for other common health conditions, according to AARP. The American Cancer Society projected that In 2025, more than 2 million people in the U.S. are expected to be diagnosed with cancer, with over 618,000 deaths projected. With these high costs, artificial intelligence (AI) is offering new solutions that are not only saving lives but also making cancer care more affordable. Early detection is one of the most effective ways to reduce cancer treatment costs. When cancer is caught in its earliest stages, treatments tend to be less aggressive and more affordable. At The Christ Hospital, AI has significantly improved lung cancer detection. 'Nearly 70% of lung cancer cases are now found at stage I or II, well above the national average of 46%,' said Seth Howard, executive vice president of research and development at Epic. 'In just six months, over 60 patients started treatment earlier, significantly improving their chances of survival.' By diagnosing cancer earlier, AI allows doctors to offer more cost-effective treatment options, which helps lower the financial burden on both patients and healthcare systems. ArteraAI is another example of how AI is transforming cancer care. Their AI technology is helping doctors determine which cancer treatments are best for their patients, preventing unnecessary therapies. 'AI is the most transformative tech we've had in a long time,' said Andre, founder of Artera. 'The impact AI has had on the healthcare system is as powerful as computers have had on the healthcare system. With the ArteraAI Prostate Test, we can personalize treatments, reducing unnecessary costs while improving outcomes.' The ArteraAI Prostate Test is fully reimbursed by Medicare under its established payment rate, meaning no out-of-pocket costs for eligible Medicare patients. This makes prostate cancer care more affordable and reduces financial strain during treatment. Surgery is often a key part of cancer treatment. Proprio, a company that has developed AI-powered surgical technology, provides surgeons with real-time data during operations, reducing the need for traditional imaging like CT scans and X-rays. This technology allows for faster surgeries, less strain on hospital staff, and quicker recovery times, which ultimately lowers the cost of care for patients. Another breakthrough demonstrating AI's transformative potential in cancer care is AION Biosystems' TempShield device. A recent study showed that TempShield, an AI-powered wearable thermometer for oncology patients, can reduce mortality rates by an astonishing 90% among cancer patients undergoing chemotherapy and inpatient hospital stays by 79%. This innovation addresses a crucial, yet often overlooked, fact: more than 50% of cancer deaths are preventable because they result from infections like pneumonia rather than cancer itself. If you spot a temperature spike (and hence an infection) early and treat it, you save lives. TempShield's continuous temperature monitoring provides clinicians with alerts up to 72 hours before symptoms of infection appear, enabling earlier intervention. 'The real danger in cancer care isn't just the disease—it's the complications we miss,' said Sam Barend, CEO of AION Biosystems. 'TempShield is a game-changer: small, simple, and affordable, and it's helping save lives by catching infections before symptoms appear—just like the blood glucose monitor did for diabetes.' AI is revolutionizing cancer care, not only improving outcomes but also making treatment more affordable. Early detection, personalized treatment, and more efficient surgeries all contribute to lowering the financial burden on patients while providing better care. With innovations like the ArteraAI Prostate Test and TempShield, AI is making cancer care smarter, more accessible, and more cost-effective for patients across the globe. As AI technologies continue to evolve, they will undoubtedly play an even greater role in both saving lives and reducing the financial strain of cancer treatment.


Bloomberg
35 minutes ago
- Bloomberg
Musk, Trump Feud: The Week That Was
President Trump and Elon Musk have been publicly mud-slinging at each other. Now, the future of SpaceX's government contracts may be easing tensions. Bloomberg's Ed Ludlow explains. (Source: Bloomberg)